Simplicity is the Ultimate Sophistication in Nanoparticle Manufacturing.

As the demand for scalable drug delivery solutions grows, research institutes and biotech organisations are stepping up to develop novel disease treatments. From CMOs and CDMOs to lipid manufacturers and pharmaceutical companies, the need for efficient, scalable technology has never been greater. The Micropore Pathfinder and Horizon series encompass these requirements, addressing both research and production needs.

Nanoparticle creation, especially for drug delivery, presents unique challenges. Microfluidic mixers (MF) introduced to the market unfortunately tend to be specific to a formulation construct, making alternative formulations difficult and time-consuming to implement. Even more concerning is their inability to scale efficiently — physics precludes it¹.

Micropore Pathfinder offers a better way to produce nanoparticles. With customisable, formulation-agnostic technology, the system can pivot to the formulation required rather than changing the formulation to fit a technology. Uninterrupted, it scales on the same mixer from microlitres to thousands of litres — all without sacrificing quality of production.

As noted by keynote speaker Dr Örn Almarsson (Axelyf) at the recent UNSW RNA Institute Symposium, the Advanced Cross Flow (AXF) technology of the Micropore Pathfinder could be a game changer in solving global scaling issues.

Democratising medicine

The Pathfinder was recently featured at Biomolecular Horizons 2024², where scientists were impressed by its flexibility, simplicity, and scalability. Some noted it’s not just a ‘black-box’ technology, a similar descriptor Prof Pieter Cullis of University of British Columbia coined. ATA Scientific presented the poster ‘Quality by design considerations in the manufacture of lipid nanoparticles’ — a presentation that was delivered at the Nanomedicines conference in Sydney, plus the Shine Dalgarno Institute at JCSMR, ANU, and at the A-RNA24³ conference where the Pathfinder was displayed for further examination.

Evaluation of the AXF technology by the Perrie Group at the University of Strathclyde further validates its potential, showing stunning results — with encapsulation efficiencies above 99%, and optimal biodistribution and efficacy. The manuscript has been accepted and awaits publication⁴.

Built from high-quality stainless steel, the Pathfinder is chemically compatible (with zero leachability), reusable and designed to handle repeated sterilisations — making it a cost-effective and environmentally sound solution for scalable nanoparticle production. Operating at just 2 bar pressure (compared to up to 140 bar in other methods), it ensures high-quality nanoparticle production with superior control and precision.

From R&D to Large-Scale Production

With enviable capacity to tune to almost any formulation, the Micropore Pathfinder range offers a package for every stage of your nanoparticle formulation journey. Whether you’re in early-stage research or preparing for clinical trials, the system is flexible enough to meet your needs. The Pathfinder Pro 125 is ideal for discovery, while the Pathfinder Pro 250 supports the transition to clinical trials. The Horizon LNP Mini is GMP-ready for large-scale production.

Discover the Future of Nanoparticle Manufacturing

The global uptake of the AXF technology is growing considerably, with systems in pharmaceutical companies, CMOs and research institutes across the planet reducing the cost of production measurably: democratising medicine.

You’re not alone in your search for scalable, high-efficiency nanoparticle technologies. Explore how the Pathfinder can transform your workflow. Contact us for a demo today!

ATA Scientific Pty Ltd
+61 2 9541 3500
enquiries@atascientific.com.au
www.atascientific.com.au

_{1. Whitepaper: A Better Way to Create Nanoparticles for in Vivo Treatments. ATA Scientific, 28 Jan 2024, www.atascientific.com.au/a-better-way-to-create-nanoparticles/}

_{2. Biomolecular Horizons 2024 Congress, Melbourne, Australia from 22–26 September 2024, https://www.bmh2024.com}

_{3. Australasian RNA Biology and Biotechnology (A-RNA) Association Meeting. 21–23 Oct 2024 Melbourne Connect. https://www.a-rna24.org.au/}

_{4. ‘Production of mRNA lipid nanoparticles using advanced crossflow micromixing’ Hussain et al, Journal of Pharmacy and Pharmacology 2024, https://doi.org/10.1093/jpp/rgae122}